Ensifentrine, marketed under the brand name Ohtuvayre, is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre, which secured FDA ...

4. Verona’s Ohtuvayre (ensifentrine) for COPD Just as Verona Pharma secured the FDA nod to market inhalable COPD drug Ohtuvayre in June, its commercial prospects seemed to improve markedly. While ...

2024 brought some major advancements in medicine. That includes the approval of "innovative" drugs like Tryvio for high blood pressure, Neffy for severe allergic reactions and Dupixent for chronic ...

expected growth as well as a full year of contribution from both Verona’s Ohtuvayre and Merck’s Capvaxive. Captisol sales are expected to rise over 30% to $35 to $40 million, propelled by an ...

The FDA’s Center for Drug Evaluation and Research (CDER) approved 50 new small molecules, biologics and oligonucleotide therapeutics last year. The class of 2024 was a little smaller than that ...

The first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor – now given the somewhat tongue-twisting brand name of Ohtuvayre – is the first inhaled product with a novel mechanism of action ...

2024 brought some major advancements in medicine. That includes the approval of "innovative" drugs like Tryvio for high blood pressure, Neffy for severe allergic reactions and Dupixent for chronic ...

9. Ohtuvayre (ensifentrine) for COPD: Approved June 26, the inhaled medication is the first new type of maintenance COPD drug in over a decade. 10. Wakix (pitolisant) for pediatric narcolepsy ...

Dupixent – which is due for a verdict from the FDA as a COPD therapy later this month – was cleared for adults with uncontrolled COPD with raised blood eosinophils, while Ohtuvayre can be used ...